Sysmex and CellaVision Expand Alliance with a View to Advancing Hematology Solutions

2024/02/06 – Kobe, Japan

Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano) announced today that the Company had entered a strategic alliance agreement (the “Agreement”) with CellaVision AB (HQ: Lund, Sweden; President & CEO: Simon Østergaard) to advance hematology solutions by expanding its portfolio, including next-generation cell morphology analyzers. Going forward, the companies will work to further increase efficiency and standardization of the testing workflow in the hematology field, increase the precision of cell morphology classification, and provide value in supporting diagnosis.

Sysmex and CellaVision entered a relationship of cooperation 20 years ago in the field of hematology, which analyzes the number, type, and size of red, white, and other blood cells. In 2001, Sysmex entered a sales alliance involving CellaVision’s cell morphology analyzers. In 2013, Sysmex launched the DI-60 Automated Digital Cell Morphology Analyzer, which was developed in collaboration with CellaVision. By connecting with Sysmex’s hematology analyzers, the system automates the process up to cell morphology analysis, contributing greatly to the streamlining and standardization of testing workflow in the hematology field in clinical laboratories around the world.

The two companies have agreed to augment their product portfolios, including next-generation cell morphology analyzers, by expanding their collaboration to advance hematology solutions, and to extend their Agreement until 2038. Based on a long-term, stable collaborative structure, the two companies intend to utilize Sysmex’s expertise in increasing efficiency and standardization of the testing workflow in the hematology field, and maximize synergies with CellaVision’s digital imaging and analysis technologies. Through these efforts, the companies aim to further enhance efficiency and standardization in the testing workflow, as well as increasing clinical value in supporting diagnoses through improved precision of cell morphology classification.

Sysmex will continue to lead the way in enhancing the value of hematology while providing high-value products and services that exceed customer expectations.


About Sysmex Corporation

Sysmex Corporation, headquartered in Kobe, Japan, is a global leader in in vitro diagnostics. Since its foundation in 1968, Sysmex has focused on diagnostics as the core of its business, and today, it supports the health of people in over 190 countries and regions worldwide. Sysmex continues to innovate in diagnostics, and to collaboratively create unique values in the areas of personalized medicine and novel treatments, under its long-term vision of "Together for a better healthcare journey." Through its unique technology, solutions, and co-creation with various partners, Sysmex delivers new value and addresses the universal desire of people to live longer and healthier lives. For more information about Sysmex, please visit


About CellaVision AB

CellaVision is a global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in healthcare services. These analyses play a vital role in swift and accurate disease diagnoses, particularly in cases of infections and serious cancer diseases. The products replace manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in sample preparation, image analysis, artificial intelligence and automated microscopy. Sales are via global partners with support from the parent company in Lund and by the company´s 13 local market support organizations covering more than 40 countries. In 2022, sales were SEK 639 million and the company's growth target is 15% per year over an economic cycle. CellaVision's registered office is in Lund, Sweden. The share is listed on the Nasdaq Stockholm, Mid Cap list. Read more at

Copyright © Sysmex Europe SE. All rights reserved.